Fragment 176-191
Also known as: HGH Frag 176-191, AOD-9604 analog
Modified growth hormone fragment focused purely on lipolysis without GH receptor activation.
Benefits
6
Conditions
4
Evidence
Preclinical studies, limited human data+ studies
Source
Synthetic hGH fragment (amino acids 176-191)
Gabriel Brain Score
Moderate
Overview
Modified growth hormone fragment focused purely on lipolysis without GH receptor activation.
Mechanism of Action
C-terminal fragment of hGH targeting beta-3 adrenergic receptors on adipocytes, stimulates lipolysis and inhibits lipogenesis, no GH receptor binding (no IGF-1 elevation or glucose effects), preferentially mobilizes stubborn fat deposits.
Key Benefits
- ✓Fat loss without muscle catabolism
- ✓No effect on blood sugar or insulin
- ✓Targets stubborn fat areas
- ✓No IGF-1 increase
- ✓Preserves lean mass
- ✓Minimal side effects
Clinical Applications
Dosing Guidelines
Subcutaneous injection
* Dosing should be individualized. Always consult with a qualified healthcare practitioner.
Research & Evidence
Preclinical studies, limited human data
Preclinical evidence for lipolysis. Human trials show good safety but mixed efficacy results for weight loss. Mechanisms well-understood but clinical validation limited.
Safety Information
Potential Side Effects
- •Minimal
- •Injection site reactions
- •Rare headache
Contraindications
- Pregnancy
- Breastfeeding
Interactions
- ⚠None well-documented
Quick Facts
Related Peptides
Retatrutide
Investigational triple agonist targeting GIP, GLP-1, and glucagon receptors for maximal metabolic benefit and weight loss.
Tirzepatide
Dual GIP and GLP-1 receptor agonist that produces superior weight loss and glycemic control compared to GLP-1 agonists alone.
Semaglutide
Long-acting GLP-1 receptor agonist that reduces appetite, improves glycemic control, and promotes significant weight loss.